Accurate Education - The 4 Domain Approach to Chronic Pain - Biomarkers

The 4 Domain Approach to Chronic Pain:

The 4-D Biomarkers

A biomarker is a measurable biological indicator in the body—such as a molecule, gene, or physical characteristic. It objectively reflects a normal biological process, a disease state, or the body’s response to a medical treatment.

Biomarkers are used in the 4-D protocols to assess the levels of activity of the four domains: systemic inflammation, neuroinflammation, oxidative stress and mitochondrial dysfunction.

See:

4-D Biomarkers – Ferritin

The 4-Domain Approach to Chronic Pain

See also:

Key to Links:

Grey text – handout
Red text – another page on this website
Blue text – Journal publication

Definitions and Terms Related to Pain

The 4-D Approach to Chronic Pain

Biomarker used in the 4-D Protocol – Part 1

High-Sensitivity C-Reactive Protein (hs-CRP)

The hs-CRP test is the most extensively validated inflammatory biomarker in clinical medicine. The 2025 ACC Scientific Statement on Inflammation and Cardiovascular Disease (CVD) now recommends universal screening of hs-CRP in both primary and secondary CVD prevention, noting that its prognostic information is “comparable with that of blood pressure and cholesterol” and that its long-term information content “appears to be at least as large as that associated with LDL cholesterol.” The established clinical thresholds —[1] <1 mg/L (lower CV risk), 1–3 mg/L (average CV risk), >3 mg/L (higher CV risk) — are well validated across large prospective studies.[1][3]

For the 4-D Protocol specifically, hs-CRP serves as the primary reflection of the systemic inflammation domain. A nationwide NHANES (National Health and Nutrition Examination Survey) cross-sectional study (n=10,680) demonstrated a linear dose-response relationship between CRP levels and chronic pain prevalence, with the highest CRP quartile (>5.2mg/L ) associated with a 32% increased risk of chronic pain compared to the lowest quartile.[4]

In osteoarthritis, a meta-analysis of 32 studies confirmed that hs-CRP levels are modestly but significantly elevated compared to controls (mean difference 1.19 mg/L) and are significantly correlated with both pain intensity (r=0.14) and decreased physical function.

Of note, hs-CRP correlated with symptoms rather than radiographic changes, suggesting it reflects pain processing rather than structural damage.[5] In fibromyalgia, a meta-analysis confirmed significantly elevated CRP levels compared to healthy controls, and a dedicated study found that higher hs-CRP correlated significantly with greater symptom burden and more tender points.[6][7]

Critically for the 4-D Protocol’s therapeutic rationale, hs-CRP is responsive to the very interventions the protocol engages. A 2026 NHANES population-level analysis demonstrated that high intake of dietary fiber, magnesium, folate, and vitamins B6, C, D, and K was significantly associated with lower hs-CRP levels.[8] Fish oil supplementation was associated with a 16% reduction in hs-CRP, and glucosamine with a 17% reduction, in a nationally representative NHANES sample.[9] This makes hs-CRP not only a diagnostic biomarker but a treatment-responsive outcome measure that can track the protocol’s efficacy over time.

Reflects: Systemic Inflammation

<1 mg/L (lower CV risk)
1–3 mg/L (average CV risk)
>3 mg/L (higher CV risk)
Target level: <1 mg/L

Omega-3 Index: Quantifying Anti-Inflammatory Fatty Acid Status

There are two commonly used biomarkers for Omega-3 fatty acids, Omega-3 Index which is used in research and reported in some commercial labs while OmegaCheck is a proprietary test reported by Quest. Both tests measure red blood cell (RBC) levels of the Omega-3 fatty acids EPA + DHA but the OmegaCheck included DPA also so the target and inflammation risk levels differ between the two tests. Both tests are validated biomarker of omega-3 tissue status.

The Omega-3 Index has been studied with well-established clinical thresholds for cardiovascular risk: <4% (high risk), 4–8% (intermediate risk), >8% (low risk/target range).[10][11] Studies estimate that moving from an Omega-3 Index of 4% to 8% would reduce fatal cardiovascular heart disease (CHD) risk by approximately 30%.[10] In the Framingham Heart Study (n=2,500), those in the highest Omega-3 Index quintile (>6.8%) had a 34% lower risk of all-cause mortality and 39% lower risk of incident CVD compared to the lowest quintile (<4.2%).[12]

The Omega-3 Index and OmegaCheck tests are particularly well suited for the 4-D Protocol because they reflect the same anti-inflammatory dietary patterns the protocol promotes. Approximately 40% of North American adults have an undesirable Omega-3 Index below 4%.[13]

A 2026 pilot RCT in older adults with chronic musculoskeletal pain demonstrated that krill oil supplementation increased the Omega-3 Index from 4.3% to 7.4%, approaching the target range, with preliminary trends favoring reduced pain intensity and fewer pain sites.[14] The target range of 8–11% is supported by comprehensive epidemiologic data linking this range to lower total mortality, cardiovascular mortality, cardiovascular events, and improved brain function.[15]

The question arises as to whether measures of Omega-3 reflect pain levels or response to Omega-3 supplementation improvement of the pain experience. This question has not been studied, but a growing number of research studies are demonstrating beneficial responses to omega-3 supplementation in multiple pain conditions. Since the 4-D protocol is not solely directed at improving chronic pain, but rather improving general health and quality of life, the use of the Omega-3 biomarker is still meaningful.

For the 4-D Protocol, the Omega-3 Index serves a dual purpose: it identifies patients with low Omega-3 status who are likely to benefit from EPA/DHA supplementation, and it provides a quantifiable target for monitoring treatment response — a feature that distinguishes it from simply prescribing a fixed dose of fish oil. That being said, in the chronic pain population at Accurate Clinic, greater than 98% of patients omega levels were below target level. Only one patient achieved target levels without the use of supplements and that patient reported eating salmon every day. It is evident in this population that routine supplementation with Omega-3 fatty acids EPA + DHA is highly desirable even in the absence of establishing a low Omega level.

Reflects: Systemic Inflammation

<4% (high risk)
4–8% (intermediate risk)
>8% (low risk)
Target level: >8%

Homocysteine

A Biomarker Bridging Neuroinflammation, Oxidative Stress, and B-Vitamin Status

Homocysteine occupies a unique position in the 4-D Protocol because it simultaneously reflects B-vitamin status (B12, folate, B6), oxidative stress, and neuroinflammatory potential. Normal total homocysteine levels are approximately 10 µmol/L, with values ≥11 µmol/L potentially justifying intervention.[16] Fasting levels of 12–30 µmol/L are classified as mild/moderate hyperhomocysteinemia, 31–100 µmol/L as intermediate, and >100 µmol/L as severe.[17] Smith and Refsum (2021) identified over 100 diseases or conditions associated with elevated homocysteine and concluded that values of ≤10 µmol/L are probably safe, while values ≥11 µmol/L “may justify intervention.”[16]

The relevance to chronic pain is direct and mechanistic. Homocysteinemia is a recognized risk factor for peripheral neuropathy, and a rodent model demonstrated that elevated homocysteine causes mechanical allodynia through upregulation of T-type calcium channels (Cav3.2) via a protein kinase C–dependent pathway — a mechanism reversed by pharmacological inhibition of these channels.[18] Homocysteine activates NMDA receptors, induces COX-2 expression, and stimulates prostaglandin E2 (PGE2) release from neurons — directly linking it to neuroinflammatory pain processing.[19] Hyperhomocysteinemia also increases production of pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α, activates NF-κB, and promotes oxidative stress through NADPH oxidase activation and nitric oxide synthase uncoupling.[20][21]

Importantly, homocysteine is readily modifiable with B-vitamin supplementation. Treatment of intermediate/severe hyperhomocysteinemia with B12 and folate reduced median homocysteine from 41 to 17 µmol/L in a cardiovascular cohort.[22] For the 4-D Protocol, elevated homocysteine identifies patients who may benefit from B-complex vitamins, B12, and P5P (pyridoxal-5′-phosphate) — three of the protocol’s nutraceuticals — while simultaneously flagging neuroinflammatory and oxidative stress contributions to their pain experience.

Reflects: Neuroinflammation, Oxidative Stress, and B-Vitamin Status

>30 µmol/L (mod to severely increased)
11–30 µmol/L (mild to mod increased)
≤10 µmol/L (normal)
Target level: ≤10 µmol/L

Methylmalonic Acid (MMA)

MMA is included in the 4-D Protocol as a more sensitive and specific marker of functional vitamin B12 deficiency than serum B12 alone. An NEJM review established that MMA levels are elevated in >98% of patients with clinical B12 deficiency, including those with only neurologic manifestations and no anemia.[23] The clinical threshold for deficiency is >0.27 µmol/L (>270 nmol/L), though nearly all patients with megaloblastic anemia or myelopathy have levels >500 nmol/L, and 86% have levels >1000 nmol/L.[23][24] Serum B12 levels alone are unreliable — up to 50% of patients with low B12 levels have no clinical deficiency, while patients with “normal” B12 can have functional deficiency detectable only by elevated MMA.[23][25]

This is clinically important for the 4-D Protocol because B12 deficiency directly impairs the neurological pathways involved in pain processing. B12 is essential for myelin synthesis, and deficiency causes demyelinating neuropathy that can present as pain, paresthesias, and sensory loss even in the absence of hematologic abnormalities.[23] MMA thus serves as a precision tool for identifying patients whose pain may have a correctable nutritional component — and for confirming adequate B12 repletion after supplementation, since MMA levels decrease immediately with effective treatment.[23]

Reflects: Functional Vitamin B12 Deficiency

>30 µmol/L (mod to severely increased)
11–30 µmol/L (mild to mod increased)
≤270 µmol/L (normal)
Target level: ≤270 µmol/L

Vitamin D (25-hydroxyvitamin D): Musculoskeletal and Immunomodulatory Assessment

Vitamin D deficiency thresholds remain debated, but the major frameworks are well established. The Endocrine Society defines <20 ng/mL as deficiency and 20–29 ng/mL as insufficiency, with ≥30 ng/mL as adequate.[26][27] The National Academy of Medicine uses a lower threshold, considering <12 ng/mL as at risk for deficiency and ≥20 ng/mL as adequate for most health outcomes.[26][24] An NEJM review (2025) noted that 2.6% of US adults have levels <25 nmol/L (<10 ng/mL), 22% have levels of 25–50 nmol/L (10–20 ng/mL), and 40.9% have levels of 50–75 nmol/L (20–30 ng/mL).[24]

For chronic pain specifically, a UK Biobank cross-sectional study of 349,221 adults found that severe vitamin D deficiency (<25 nmol/L or <10 ng/mL) was significantly associated with chronic widespread pain (OR 1.26; 95% CI 1.07–1.49) even after adjusting for all confounding factors, though associations with regional pain were attenuated after confounder adjustment.[28] The Cochrane review (2015) found no consistent pattern that vitamin D supplementation was superior to placebo across chronic pain conditions, but noted significant methodological limitations and suggested that future research should examine whether effects are restricted to patients who are vitamin D deficient.[29] This is precisely the 4-D Protocol’s approach — measuring vitamin D to identify deficient patients rather than supplementing empirically.

Vitamin D’s relevance to the 4-D Protocol extends beyond direct analgesic effects. The 2026 NHANES analysis demonstrated that vitamin D intake was significantly associated with lower hs-CRP levels (1.3 vs. 3.8 mg/L for high vs. low intake).[8] Vitamin D deficiency promotes pro-inflammatory cytokine production and impairs immune regulation — mechanisms that feed directly into the systemic inflammation and neuroinflammation domains.

Measures Systemic Vit D3 levels (but may reflect systemic inflammation and neuroinflammation)

<10 ng/mL (severe deficiency)
<25 ng/mL (deficiency)
25–29 ng/mL (insufficiency)
>30 ng/mL (adequate)
40–60 ng/mL (optimal)
>120 ng/mL (potentially toxic)
Target level: 40–60 ng/mL

Coenzyme Q10 (CoQ10): May Reflect Mitochondrial Function and Oxidative Stress

Note: CoQ10 is not considered a reliable biomarker for the mitochondrial dysfunction or oxidative stress domains. While plasma CoQ10 concentration can be measured, “it is unclear whether such measurements reflect actual tissue status.” See CoQ10 below

This means that serum CoQ10 levels are a unreliable guides for clinical decision-making in most patients — the variability introduced by diet, formulation, timing of measurement, and the disconnect between plasma and tissue levels makes them unreliable for directing supplementation. However, in some conditions CoQ10 levels may be checked as a relative monitor prior to and during treatment to assess changes in an individual’s trends. The approach of supplementing CoQ10 based on clinical condition (fibromyalgia, statin use, diabetes/pre-diabetes, mitochondrial dysfunction features) rather than serum levels is pragmatically sound – See CoQ10 below

While standardized population-level reference ranges are less firmly established than for the biomarkers above, the clinical evidence linking CoQ10 depletion to chronic pain — particularly fibromyalgia — is substantial. Multiple studies have demonstrated that CoQ10 levels are reduced in fibromyalgia patients compared to healthy controls, and that this reduction correlates with worsening symptoms.[30][31][32] Cordero et al. (2013) conducted an RCT demonstrating that CoQ10 supplementation (300 mg/day for 40 days) produced significant reductions in FIQ scores, pain, fatigue, and morning tiredness, with concurrent recovery of inflammation markers, antioxidant enzymes, and mitochondrial biogenesis gene expression.[31] CoQ10 combined with pregabalin significantly reduced pain and anxiety compared to pregabalin monotherapy.[30]

CoQ10 supplementation has also been shown to improve skeletal muscle mitochondrial bioenergetics and reduce inflammation markers in an arthritis model, with combined CoQ10 and omega-3 treatment affecting inflammation and antioxidant status more intensively than either monotherapy.[33] A 2026 study confirmed that CoQ10 supplementation in a fibromyalgia model restored muscular CoQ10 levels, reduced oxidative damage markers, and upregulated AMPK, SIRT1, and PGC-1α — key regulators of mitochondrial biogenesis.[34]

For the 4-D Protocol, CoQ10 measurement identifies patients with mitochondrial dysfunction who are likely to respond to targeted supplementation, and provides a rationale for combining CoQ10 with other mitochondrial-support nutraceuticals (alpha-lipoic acid, nicotinamide riboside, D-ribose) based on the severity of the mitochondrial dysfunction domain.

May reflect Mitochondrial Dysfunction and Oxidative Stress

Kynurenine Pathway Metabolites: The Neuroinflammation Frontier

Note: Currently, measures of these metabolites are available only at specialty commercial labs, and are not covered by insurance. In the future, if and when these measures are affordable and reliable, they may be incorporated into the 40 protocols.

The kynurenine pathway — the primary route for tryptophan degradation — represents an emerging but increasingly validated biomarker system for the neuroinflammation domain. The kynurenine-to-tryptophan (KYN/TRP) ratio serves as a marker of indoleamine 2,3-dioxygenase (IDO) activity, which is upregulated by pro-inflammatory cytokines.[35][36][37] In diabetic neuropathic pain, the KYN/TRP ratio was elevated and positively correlated with pain intensity.[37] In fibromyalgia, the neuroprotective ratio (kynurenic acid/3-hydroxykynurenine) was significantly lower than in healthy controls and was associated with increased pain symptoms.[38]

The kynurenine pathway may become particularly relevant to the 4-D Protocol because it sits at the intersection of neuroinflammation, oxidative stress, and mitochondrial dysfunction. Quinolinic acid (a neurotoxic kynurenine metabolite) activates NMDA receptors and generates reactive oxygen species, while kynurenic acid (a neuroprotective metabolite) antagonizes NMDA receptors.[36][39] The balance between these metabolites — modifiable through anti-inflammatory interventions — determines whether the pathway amplifies or attenuates pain processing.[35][40]

Reflects Neuroinflammation

The Integrated Biomarker Panel: Why These Markers Together

The strength of the 4-D Protocol’s biomarker panel lies not in any single marker but in the convergent information they provide across the four domains:

Biomarker	Domain(s) Assessed	Clinical Threshold	Key Evidence	References
hs-CRP	Systemic Inflammation	<1 mg/L desirable; >3 mg/L elevated risk	ACC universal screening recommendation; linear association with chronic pain (NHANES n=10,680); correlated with OA pain and FM symptom burden	[1], [2], [3], [4]
Omega-3 Index	Systemic Inflammation, Neuroinflammation	<4% high risk; 8–11% target	10-cohort analysis: ~30% CHD risk reduction from 4%→8%; Framingham: 34% lower all-cause mortality in highest quintile	[5], [6], [7]
Homocysteine	Neuroinflammation, Oxidative Stress, B-Vitamin Status	≤10 µmol/L safe; ≥11 µmol/L may justify intervention	>100 disease associations; causes mechanical allodynia via Cav3.2 channels; induces COX-2/PGE2 in neurons	[8], [9], [10]
Methylmalonic Acid	B12 Functional Status, Neuroinflammation	>270 nmol/L suggests deficiency	Elevated in >98% of clinical B12 deficiency; more specific than serum B12; decreases immediately with treatment	[11], [12]
25(OH) Vitamin D	Systemic Inflammation, Musculoskeletal	<20 ng/mL deficiency (Endocrine Society); <30 nmol/L severe deficiency	Severe deficiency associated with chronic widespread pain (OR 1.26, UK Biobank n=349,221); intake inversely associated with hs-CRP	[13], [14], [15]
CoQ10	Mitochondrial Dysfunction, Oxidative Stress	Reduced levels correlate with FM severity	RCT: 300 mg/day reduced pain, fatigue; restored mitochondrial biogenesis markers; synergistic with pregabalin	[16], [17], [18]
KYN/TRP Ratio	Neuroinflammation (Not Available)	Elevated ratio indicates IDO activation	Positively correlated with pain intensity in diabetic neuropathy; altered neuroprotective ratios in FM	[19], [20]

Each biomarker is individually validated in clinical medicine, has established or emerging thresholds, is modifiable by the protocol’s interventions, and provides information about a specific pathogenic domain. Together, they create a quantifiable biochemical profile that transforms chronic pain assessment from a purely subjective exercise into one grounded in objective, measurable, and treatable biology — the same biology that underlies the anti-inflammatory diet’s well-established health benefits.

Biomarker used in the 4-D Protocol – Part 2

—

Gamma-Glutamyl Transferase (GGT)

GGT is traditionally ordered as a liver function biomarker, but its biological function is far more fundamental. GGT is a cell-surface enzyme that regulates the metabolism of glutathione (GSH) — the most abundant intracellular antioxidant. By hydrolyzing extracellular GSH, GGT provides the cell with cysteine for de novo intracellular GSH synthesis, making it a critical regulator of redox homeostasis.[1] When oxidative stress increases, GGT is upregulated as a compensatory response to maintain intracellular antioxidant capacity. Elevated circulating GGT therefore serves as a signal that the organism is under oxidative stress and is attempting to replenish its antioxidant defenses.

This re-interpretation is supported by a large retrospective study of 168,858 patients across 44 disease categories, which demonstrated that 38 of 44 diseases had significantly increased GGT activity compared to healthy controls. The authors concluded that circulating GGT is a “long-sought biomarker of redox status in blood circulation.” Importantly, GGT elevation was observed not only in liver diseases but across cardiovascular disease, diabetes, hyperuricemia, inflammation, renal insufficiency, and cancer — all conditions characterized by oxidative stress.[2] GGT has also been specifically implicated in neuroinflammation and bone disorders, extending its relevance beyond hepatobiliary pathology.[3]

However, GGT also has a paradoxical “dark side.” During its metabolic function, GGT can generate pro-oxidant reactions — the very process of cleaving extracellular GSH can produce cysteinyl-glycine, which in the presence of iron catalyzes Fenton reactions generating reactive oxygen species. This means elevated GGT is not merely a passive marker of oxidative stress but may actively participate in its propagation, particularly in atherosclerotic plaques where catalytically active GGT has been identified and correlated with indices of plaque instability.[3][4][5]

The cardiovascular risk data provide the strongest clinical validation for GGT thresholds. A dose-response meta-analysis of 9 prospective studies (n=527,589) demonstrated that each 10 U/L increase in GGT was associated with a 10% increase in cardiovascular mortality (HR 1.10; 95% CI 1.08–1.11), with the highest GGT levels conferring a 59% increased risk (HR 1.59; 95% CI 1.47–1.72).[6] A UK Biobank analysis found that GGT concentrations as low as ≥16 U/L in men and ≥9 U/L in women were associated with a 71% increased risk of heart failure — well within the conventional “normal” reference range.[7] A Korean cohort study of 419,433 subjects confirmed a dose-response relationship between GGT quartiles and atherosclerotic cardiovascular disease (HR 1.23 for highest vs. lowest quartile).[8] A meta-analysis of prospective cohort studies (>1.23 million participants) found a pooled RR of 1.23 (95% CI 1.16–1.29) for CVD per 1-SD change in log GGT, with a log-linear relationship.[9]

For the 4-D Protocol, GGT’s value lies in its unique position as a routinely available, inexpensive, insurance-covered laboratory test that provides information about the oxidative stress domain. Standard laboratory reference ranges (typically <55–65 U/L for men, <38–45 U/L for women) were established for hepatobiliary screening and likely underestimate the threshold at which GGT reflects clinically meaningful oxidative stress. The cardiovascular literature suggests that risk begins to increase at levels well within the conventional normal range, supporting the use of lower thresholds for domain profiling purposes. Pending further research, for using the protocols less than 30 U/L is assessed to be normal while values greater than 50 U/L are likely associated with increased oxidative stress

Reflects Oxidative Stress

<30 U/L (Normal)
>50 µU/L (High)

—

Serum Uric Acid: A Dual-Role Biomarker Bridging Oxidative Stress and Inflammation

Uric acid occupies a unique and somewhat paradoxical position in redox biology. At physiological concentrations, uric acid is a potent antioxidant responsible for approximately 50% of serum antioxidant activity and contributing to about 70% of all free radical scavenging in human plasma.[10] However, at elevated concentrations and in hydrophobic environments, uric acid becomes a strong pro-oxidant — generating reactive oxygen species, activating NADPH oxidase, and promoting endothelial dysfunction through reduced nitric oxide bioavailability.[10]

A cross-sectional study of 192 health examination participants demonstrated that serum uric acid was significantly associated with increased oxidative stress (measured by d-ROMs) independent of xanthine oxidoreductase (XOR) activity — meaning the prooxidant effect of uric acid is not simply a byproduct of its production but an intrinsic property of the molecule itself.[11] This is a critical distinction: it means that elevated uric acid is not merely a marker of increased purine metabolism but an active contributor to oxidative stress.

The inflammatory dimension is equally compelling. A study of 333 asymptomatic young patients with primary hyperuricemia (no gout, no clinical symptoms) demonstrated that as uric acid levels increased, MDA (lipid peroxidation marker) increased significantly, SOD (antioxidant enzyme) decreased significantly, and both IL-6 and TNF-α increased significantly. Uric acid was an independent risk factor for elevated IL-6 (OR 2.38) and TNF-α (OR 3.26).[12] Mechanistically, high uric acid promotes M1 macrophage polarization and inflammatory cytokine production through the HMGB1-RAGE-ROS axis, and this extends beyond gout to contribute to the pathogenesis of atherosclerosis, metabolic syndrome, and other inflammatory conditions.[13] Hyperuricemia also induces mitochondrial functional disturbances and decreased ATP content, linking it directly to the mitochondrial dysfunction domain.[10]

The evidence linking uric acid to non-gouty chronic pain is particularly relevant for the 4-D Protocol:

1. A prospective study of 124 women with chronic musculoskeletal pain followed for 1 year found that an initially high serum uric acid level was the strongest independent predictor of increased pain extension over 12 months (OR 4.46), and changes in uric acid correlated significantly with changes in the number of pain locations (r=0.36).[14]
2. A population-based study from Norway found that persons with chronic widespread, weather-dependent complaints had the highest uric acid values, and odds ratios for this subgroup increased with increasing uric acid levels — with the authors concluding that “uric acid needs attention in future studies on chronic widespread musculoskeletal complaints.”[15]
3. A 2025 Finnish population-based cohort study demonstrated that hyperuricemic individuals used significantly more analgesics than normouricemic individuals, with purchases of non-NSAID analgesics increasing from ~250 to ~800 per 1,000 person-years as uric acid rose from 360 to 800 µmol/L. The inflection point was at 360 µmol/L (~6 mg/dL) — the standard hyperuricemia threshold. The authors concluded that “even in the absence of gout attacks, heightened SUA levels are associated with more frequent or intense pain.”[16]
4. In healthy subjects without neuropathy, higher uric acid levels correlated with lower sensory nerve function on electrophysiological testing, suggesting a subclinical neurotoxic effect on peripheral nerves.[17]
5. A 2025 study of knee osteoarthritis demonstrated that serum uric acid was the only independent risk factor for both high-grade synovitis and severe pain in multivariate analysis, with uric acid positively correlated with synovial fluid inflammatory cytokine levels — even in non-gout patients.[18]

The clinical threshold of >6 mg/dL (360 µmol/L) for hyperuricemia is well established and aligns with the inflection point identified in the Finnish analgesic-use study.[16] For the 4-D Protocol, uric acid serves as a readily available, inexpensive biomarker that simultaneously reflects oxidative stress burden, inflammatory activation, and mitochondrial stress — spanning three of the four domains.

Reflects Systemic Inflammation, Mitochondrial Function and Oxidative Stress

—

Serum Ferritin: A Bidirectional Biomarker of Iron Status and Inflammation

Ferritin is unique among the 4-D Protocol biomarkers because it provides clinically actionable information in both directions — low ferritin signals iron deficiency that may contribute to pain through impaired neurotransmitter synthesis, while elevated ferritin signals inflammation and/or iron overload that may drive oxidative stress.

An NEJM review on humoral innate immunity established that ferritin is an acute-phase protein that is upregulated during the acute-phase reaction, independent of iron stores. In chronic inflammatory diseases, ferritin levels are characteristically elevated because of cytokine-driven induction rather than iron excess.[19] The Cochrane review on ferritin as a diagnostic test confirmed that ferritin is “increased in acute and chronic inflammation due to infection, inflammatory illnesses and malignancy,” and that coexistent iron deficiency and inflammation can result in relative increases in ferritin that mask true iron deficiency.[20] Hyperferritinemia is observed across rheumatologic diseases, infections, and malignancies, with CRP identified as an independent predictor of mortality in hyperferritinemic patients.[21]

The relevance of low ferritin to chronic pain — particularly fibromyalgia — is supported by several lines of evidence:

1. A case-control study found that fibromyalgia patients had significantly reduced serum ferritin compared to healthy controls (27.3 vs. 43.8 ng/mL,), and having a ferritin level <50 ng/mL conferred a 6.5-fold increased risk of fibromyalgia.[22]
2. A Taiwanese nationwide population-based cohort study (n=13,381 IDA patients) demonstrated that iron deficiency anemia was associated with a 19% increased risk of developing fibromyalgia. Notably, patients who received both iron supplementation and blood transfusion had a 27% reduced risk compared to the non-IDA reference group.[23]
3. A Mendelian randomization study using GWAS data confirmed a causal negative association between iron levels and fibromyalgia risk, providing genetic evidence that iron deficiency is not merely correlated with but may causally contribute to fibromyalgia.[24]
4. A placebo-controlled trial of ferric carboxymaltose in 80 women with fibromyalgia demonstrated that iron supplementation improved FIQR scores, enhanced Brief Pain Inventory scores, and reduced fatigue after 42 days.[25]

The mechanistic rationale is straightforward: iron is an essential cofactor for the enzymes that synthesize serotonin, dopamine, and norepinephrine — the very neurotransmitters that drive the descending modulatory pain pathways targeted by the 4-D Protocol.[22] Iron deficiency impairs this synthesis, potentially contributing to the descending pain modulation dysfunction that characterizes chronic pain states.

However, one study of non-anemic fibromyalgia patients found no significant differences in ferritin between FM patients and controls, and no correlation between iron parameters and FIQ scores — suggesting that the relationship may be most relevant in patients with actual iron deficiency or low-normal ferritin rather than across all FM patients.[26]

For the 4-D Protocol, ferritin interpretation requires clinical context:

1. Low ferritin (<30–50 ng/mL): Suggests iron deficiency that may impair neurotransmitter synthesis and contribute to pain processing dysfunction, warranting iron repletion
2. Normal ferritin with elevated CRP: May mask underlying iron deficiency (functional iron deficiency in the setting of inflammation), requiring additional markers such as transferrin saturation or soluble transferrin receptor
3. Elevated ferritin (>200–300 ng/mL in women, >300–400 ng/mL in men) with elevated CRP: Likely reflects the acute-phase response and confirms systemic inflammation domain involvement
4. Elevated ferritin with normal CRP: Should prompt evaluation for iron overload, hemochromatosis, or other causes

Integrating Ferritin into the 4-D Protocol’s Domain Profiling

For the 4-D Protocol, ferritin’s value lies in its ability to inform two domains simultaneously:

Ferritin Level	CRP Status	Domain Implication	Clinical Action	Ref
<30 ng/mL	Any	Neuroinflammation (impaired neurotransmitter synthesis)	Confirm with transferrin saturation (TSAT) initiate iron repletion; evaluate cause	[1], [2]
30–50 ng/mL	Normal	Borderline — particularly relevant in FM phenotype (6.5× risk if <50)	Obtain transferrin saturation (TSAT) consider iron repletion if TSAT <20% or FM phenotype	[2], [3]
50–100 ng/mL	Elevated CRP (>3 mg/L)	Possible functional iron deficiency masked by inflammation	Obtain transferrin saturation (TSAT) if <20%, iron deficiency likely despite “normal” ferritin; consider ferritin/CRP ratio ≤6	[1], [4], [5]
>200 (F) >300 (M) ng/mL	Normal	Possible iron overload	Obtain transferrin saturation (TSAT) if ≥45%, proceed to HFE genotyping	[6], [7], [8]
>200 (F) >300 (M) ng/mL	Elevated CRP (>3 mg/L)	Likely acute-phase response confirming systemic inflammation domain	Confirms inflammation domain; transferrin saturation (TSAT) helps exclude concurrent iron overload	[7], [9], [10]
>500 ng/mL	Any	Warrants urgent evaluation regardless of CRP	Full workup including TSAT, HFE genotyping, liver evaluation; consider malignancy, infection, hematologic disorder	[11], [12]

The critical insight for the 4-D Protocol is that conventional “normal” ferritin ranges (20–200 ng/mL in women, 40–300 ng/mL in men) were established for detecting iron-deficiency anemia, not for optimizing neurotransmitter synthesis or pain processing. The fibromyalgia data suggest that ferritin levels well within the “normal” range (<50 ng/mL) may be clinically significant for pain processing, and the inflammation data demonstrate that ferritin levels that appear “normal” may actually mask iron deficiency when CRP is elevated. Both of these nuances are directly relevant to the 4-D Protocol’s goal of identifying modifiable biochemical contributors to pain severity.

Note: Abnormal Ferritin levels require a complex response for further diagnostic assessment and treatment: See: Ferritin

May Reflect Bidirectional Impairment:

If <30 ng/mL: Reflects neuroinflammation
If >200 ng/mL (F): Reflects Systemic Inflammation
If >300 ng/mL (M): Reflects Systemic Inflammation

CoQ10: A Nutraceutical Supplementation Without a Reliable Biomarker — And That’s Acceptable

The decision to include CoQ10 as a nutraceutical without relying on serum CoQ10 levels as a biomarker is well supported by the literature. A JACC Focus Seminar review stated explicitly that while plasma CoQ10 concentration can be measured, “it is unclear whether such measurements reflect actual tissue status.” The reference interval in a US population ranges from 0.50 to 1.91 µmol/L with sex and racial differences, and there is[27] no established minimum or maximum effective dose — in cardiac trials, doses of 100–400 mg have been used, while neurodegenerative disease trials have used 600–3,000 mg.[27] Dietary changes or single doses cause little or no change in plasma concentration, though chronic supplementation does increase levels depending on dose, duration, and formulation.[27]

This means that serum CoQ10 levels are a poor guide for clinical decision-making in most patients — the variability introduced by diet, formulation, timing of measurement, and the disconnect between plasma and tissue levels makes them unreliable for directing supplementation. The approach of supplementing CoQ10 based on clinical phenotype (fibromyalgia, statin use, diabetes/pre-diabetes, mitochondrial dysfunction features) rather than serum levels is pragmatically sound. The RCT evidence for CoQ10 in fibromyalgia (300 mg/day producing significant reductions in pain, fatigue, and morning tiredness with concurrent recovery of inflammation markers and mitochondrial biogenesis gene expression) supports supplementation based on clinical indication rather than serum measurement.[28]

The exception noted — measuring CoQ10 in pre-diabetic and diabetic patients — is reasonable given the established association between CoQ10 depletion and metabolic disease, and the potential for statin-induced CoQ10 depletion in this population.[29] Expanding this to fibromyalgia patients is supported by the evidence that FM patients have reduced CoQ10 levels compared to controls, though the clinical utility of the measurement remains limited by the same plasma-tissue disconnect.[25]

—

Summary: The Biomarker Panel in Context

Biomarker	Primary Domain(s)	Key Threshold(s)	Strength of Evidence for Pain Relevance	Availability/Cost	Ref.
GGT	Oxidative Stress, Systemic Inflammation	Standard lab range; CV risk increases at ≥16 U/L (men), ≥9 U/L (women) per UK Biobank	Strong for oxidative stress/CV risk; indirect for pain	Routine, inexpensive, universally covered	[1], [2], [3]
Uric Acid	Oxidative Stress, Systemic Inflammation, Mitochondrial Dysfunction	>6 mg/dL (360 µmol/L) hyperuricemia threshold; pain inflection at same level	Strong — prospective pain data, dose-response analgesic use, MR evidence	Routine, inexpensive, universally covered	[4], [5], [6], [7]
Ferritin	Systemic Inflammation (elevated), Neuroinflammation/neurotransmitter synthesis (low)	<30–50 ng/mL (iron deficiency risk for FM); elevated = acute phase reactant	Strong — 6.5× FM risk if <50 ng/mL; MR causal evidence for iron-FM link; RCT showing improvement with iron repletion	Routine, inexpensive, universally covered	[8], [9], [10], [11]
CoQ10 (serum)	Mitochondrial Dysfunction	No established clinical threshold; plasma may not reflect tissue status	Limited as biomarker; strong as nutraceutical based on clinical phenotype	Available but not routinely covered; variable	[12]

The strength of GGT, uric acid, and ferritin as 4-D Protocol biomarkers lies in their convergence of three critical features: they are routinely available and insurance-covered, they reflect the specific pathogenic domains the protocol targets, and they are modifiable by the protocol’s interventions (anti-inflammatory diet, nutraceuticals, lifestyle modification). This makes them practical tools for both initial domain profiling and longitudinal treatment monitoring in outpatient pain management.

References – Part 1

Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement: A Report of the American College of Cardiology. Mensah GA, Arnold N, Prabhu SD, Ridker PM, Welty FK. Journal of the American College of Cardiology. 2025;:S0735-1097(25)07555-2. doi:10.1016/j.jacc.2025.08.047.
Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement: A Report of the American College of Cardiology. Mensah GA, Arnold N, Prabhu SD, Ridker PM, Welty FK. Journal of the American College of Cardiology. 2025;:S0735-1097(25)07555-2. doi:10.1016/j.jacc.2025.08.047.
A Test in Context: High-Sensitivity C-Reactive Protein. Ridker PM. Journal of the American College of Cardiology. 2016;67(6):712-723. doi:10.1016/j.jacc.2015.11.037.
Association Between C-Reactive Protein and Chronic Pain in US Adults: A Nationwide Cross-Sectional Study. Huang C, Tong Q, Tong Q. PloS One. 2025;20(2):e0315602. doi:10.1371/journal.pone.0315602.
Circulating C Reactive Protein in Osteoarthritis: A Systematic Review and Meta-Analysis. Jin X, Beguerie JR, Zhang W, et al. Annals of the Rheumatic Diseases. 2015;74(4):703-10. doi:10.1136/annrheumdis-2013-204494.
Potential Role of Blood Biomarkers in Patients With Fibromyalgia: A Systematic Review With Meta-Analysis. Kumbhare D, Hassan S, Diep D, et al. Pain. 2022;163(7):1232-1253. doi:10.1097/j.pain.0000000000002510.
Elevated High Sensitive C-Reactive Protein in Fibromyalgia. Beiner E, Brenner Miguel S, Friederich HC, Tesarz J. Frontiers in Psychiatry. 2023;14:1237518. doi:10.3389/fpsyt.2023.1237518.
Daily Nutrient Intake and Inflammation Among US Adults. Mainous AG, Yin L, Orlando FA, Saguil AA. Journal of the American Board of Family Medicine : JABFM. 2026;39(1):162211. doi:10.3122/jabfm.2025.250393R1.
Association Between Use of Specialty Dietary Supplements and C-Reactive Protein Concentrations. Kantor ED, Lampe JW, Vaughan TL, et al. American Journal of Epidemiology. 2012;176(11):1002-13. doi:10.1093/aje/kws186.
The Omega-3 Index and Relative Risk for Coronary Heart Disease Mortality: Estimation From 10 Cohort Studies. Harris WS, Del Gobbo L, Tintle NL. Atherosclerosis. 2017;262:51-54. doi:10.1016/j.atherosclerosis.2017.05.007.
The Omega-3 Index as a Risk Factor for Coronary Heart Disease. Harris WS. The American Journal of Clinical Nutrition. 2008;87(6):1997S-2002S. doi:10.1093/ajcn/87.6.1997S.
Erythrocyte Long-Chain Omega-3 Fatty Acid Levels Are Inversely Associated With Mortality and With Incident Cardiovascular Disease: The Framingham Heart Study. Harris WS, Tintle NL, Etherton MR, Vasan RS. Journal of Clinical Lipidology. 2018 May – Jun;12(3):718-727.e6. doi:10.1016/j.jacl.2018.02.010.
Proportions of Long-Chain Ω-3 Fatty Acids in Erythrocyte Membranes of Canadian Adults: Results From the Canadian Health Measures Survey 2012-2015. Demonty I, Langlois K, Greene-Finestone LS, Zoka R, Nguyen L. The American Journal of Clinical Nutrition. 2021;113(4):993-1008. doi:10.1093/ajcn/nqaa401.
Pilot Randomized Controlled Trial of Krill Oil Supplementation for Chronic Musculoskeletal Pain in Older Adults. Tamargo JA, Carvajal E, Simic K, et al. The Journal of Nutrition. 2026;156(6):101517. doi:10.1016/j.tjnut.2026.101517.
Omega-3 Index in 2018/19. von Schacky C. The Proceedings of the Nutrition Society. 2020;:1-7. doi:10.1017/S0029665120006989.
Homocysteine – From Disease Biomarker to Disease Prevention. Smith AD, Refsum H. Journal of Internal Medicine. 2021;290(4):826-854. doi:10.1111/joim.13279.
Homocysteine-Lowering Interventions for Preventing Cardiovascular Events. Martí-Carvajal AJ, Solà I, Lathyris D, Dayer M. The Cochrane Database of Systematic Reviews. 2017;8:CD006612. doi:10.1002/14651858.CD006612.pub5.
A Potential Role for T-Type Calcium Channels in Homocysteinemia-Induced Peripheral Neuropathy. Gaifullina AS, Lazniewska J, Gerasimova EV, et al. Pain. 2019;160(12):2798-2810. doi:10.1097/j.pain.0000000000001669.
Role of GluN2A NMDA Receptor in Homocysteine-Induced Prostaglandin E2 Release From Neurons. Rajagopal S, Fitzgerald AA, Deep SN, Paul S, Poddar R. Journal of Neurochemistry. 2019;150(1):44-55. doi:10.1111/jnc.14775.
Homocysteine and Homocysteine-Related Compounds: An Overview of the Roles in the Pathology of the Cardiovascular and Nervous Systems. Djuric D, Jakovljevic V, Zivkovic V, Srejovic I. Canadian Journal of Physiology and Pharmacology. 2018;96(10):991-1003. doi:10.1139/cjpp-2018-0112.
Uncovering Hyperhomocysteinemia: Global Risk Patterns and Molecular Disruption in Brain and Vascular Health. Ramires Júnior OV, Prauchner GRK, Rieder AS, et al. Journal of Neurochemistry. 2025;169(12):e70327. doi:10.1111/jnc.70327.
Cardiovascular Manifestations of Intermediate and Major Hyperhomocysteinemia Due to Vitamin B12 and Folate Deficiency and/or Inherited Disorders of One-Carbon Metabolism: A 3.5-Year Retrospective Cross-Sectional Study of Consecutive Patients. Levy J, Rodriguez-Guéant RM, Oussalah A, et al. The American Journal of Clinical Nutrition. 2021;113(5):1157-1167. doi:10.1093/ajcn/nqaa432.
Vitamin B12 Deficiency. Stabler SP. The New England Journal of Medicine. 2013;368(2):149-60. doi:10.1056/NEJMcp1113996.
Micronutrients — Assessment, Requirements, Deficiencies, and Interventions. Allen LH. The New England Journal of Medicine. 2025;392(10):1006-1016. doi:10.1056/NEJMra2314150.
Methylmalonic Acid and Homocysteine as Indicators of Vitamin B-12 Deficiency in Cancer. Vashi P, Edwin P, Popiel B, Lammersfeld C, Gupta D. PloS One. 2016;11(1):e0147843. doi:10.1371/journal.pone.0147843.
Vitamin D, Calcium Supplements, And Implications for Cardiovascular Health: JACC Focus Seminar. Michos ED, Cainzos-Achirica M, Heravi AS, Appel LJ. Journal of the American College of Cardiology. 2021;77(4):437-449. doi:10.1016/j.jacc.2020.09.617.
Revisiting Vitamin D Guidelines: A Critical Appraisal of the Literature. Holick MF. Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2024;30(12):1227-1241. doi:10.1016/j.eprac.2024.10.011.
Serum Vitamin D and Chronic Musculoskeletal Pain: A Cross-Sectional Study of 349,221 Adults in the UK. Xie Y, Farrell SF, Armfield N, Sterling M. The Journal of Pain. 2024;25(9):104557. doi:10.1016/j.jpain.2024.104557.
Vitamin D for the Treatment of Chronic Painful Conditions in Adults. Straube S, Derry S, Straube C, Moore RA. The Cochrane Database of Systematic Reviews. 2015;(5):CD007771. doi:10.1002/14651858.CD007771.pub3.
Oxidative Stress in Fibromyalgia: From Pathology to Treatment. Assavarittirong C, Samborski W, Grygiel-Górniak B. Oxidative Medicine and Cellular Longevity. 2022;2022:1582432. doi:10.1155/2022/1582432.
Can Coenzyme Q10 Improve Clinical and Molecular Parameters in Fibromyalgia?. Cordero MD, Alcocer-Gómez E, de Miguel M, et al. Antioxidants & Redox Signaling. 2013;19(12):1356-61. doi:10.1089/ars.2013.5260.
Oxidative Stress Correlates With Headache Symptoms in Fibromyalgia: Coenzyme Q₁₀ Effect on Clinical Improvement. Cordero MD, Cano-García FJ, Alcocer-Gómez E, De Miguel M, Sánchez-Alcázar JA. PloS One. 2012;7(4):e35677. doi:10.1371/journal.pone.0035677.
Treatment With Coenzyme Q10, Omega-3-Polyunsaturated Fatty Acids and Their Combination Improved Bioenergetics and Levels of Coenzyme Q9 and Q10 in Skeletal Muscle Mitochondria in Experimental Model of Arthritis. Kucharská J, Poništ S, Vančová O, et al. Physiological Research. 2021;70(5):723-733. doi:10.33549/physiolres.934664.
Coenzyme Q10 Improves Redox Homeostasis, Mitochondrial Biogenesis, and Irisin Signaling in Fast- And Slow-Twitch Muscle Fibers in a Reserpine-Induced Fibromyalgia-Like Myalgia Model. Belviranlı M, Okudan N, Sezer T. Life Sciences. 2026;394:124366. doi:10.1016/j.lfs.2026.124366.
Kynurenine Pathway Metabolites as Potential Biomarkers in Chronic Pain. Auyeung A, Wang HC, Aravagiri K, Knezevic NN. Pharmaceuticals (Basel, Switzerland). 2023;16(5):681. doi:10.3390/ph16050681.
Understanding the Kynurenine Pathway: A Narrative Review on Its Impact Across Chronic Pain Conditions. Hazrati E, Eftekhar SP, Mosaed R, Shiralizadeh Dini S, Namazi M. Molecular Pain. 2024 Jan-Dec;20:17448069241275097. doi:10.1177/17448069241275097.
Kynurenine, Tetrahydrobiopterin, and Cytokine Inflammatory Biomarkers in Individuals Affected by Diabetic Neuropathic Pain. Staats Pires A, Heng B, Tan VX, et al. Frontiers in Neuroscience. 2020;14:890. doi:10.3389/fnins.2020.00890.
Kynurenine Metabolites and Ratios Differ Between Chronic Fatigue Syndrome, Fibromyalgia, and Healthy Controls. Groven N, Reitan SK, Fors EA, Guzey IC. Psychoneuroendocrinology. 2021;131:105287. doi:10.1016/j.psyneuen.2021.105287.
Tryptophan Metabolism as a ‘Reflex’ Feature of Neuroimmune Communication: Sensor and Effector Functions for the Indoleamine-2, 3-Dioxygenase Kynurenine Pathway. Stone TW, Williams RO. Journal of Neurochemistry. 2024;168(9):3333-3357. doi:10.1111/jnc.16015.
Recent Advances in Clinical Trials Targeting the Kynurenine Pathway. Pires AS, Sundaram G, Heng B, et al. Pharmacology & Therapeutics. 2022;236:108055. doi:10.1016/j.pharmthera.2021.108055.

References – Part 2

Targeting Gamma-Glutamyl Transpeptidase: A Pleiotropic Enzyme Involved in Glutathione Metabolism and in the Control of Redox Homeostasis. Mitrić A, Castellano I. Free Radical Biology & Medicine. 2023;208:672-683. doi:10.1016/j.freeradbiomed.2023.09.020.
Gamma‐Glutamyltransferase Activity (GGT) Is a Long‐Sought Biomarker of Redox Status in Blood Circulation: A Retrospective Clinical Study of 44 Types of Human Diseases. Bai C, Zhang M, Zhang Y, et al. Oxidative Medicine and Cellular Longevity. 2022;2022:8494076. doi:10.1155/2022/8494076.
The Dark Side of Gamma-Glutamyltransferase (GGT): Pathogenic Effects of an ‘Antioxidant’ Enzyme. Corti A, Belcastro E, Dominici S, Maellaro E, Pompella A. Free Radical Biology & Medicine. 2020;160:807-819. doi:10.1016/j.freeradbiomed.2020.09.005.
Gamma-Glutamyl Transferase and the Risk of Atherosclerosis and Coronary Heart Disease. Ndrepepa G, Colleran R, Kastrati A. Clinica Chimica Acta; International Journal of Clinical Chemistry. 2018;476:130-138. doi:10.1016/j.cca.2017.11.026.
Association between Gamma‐Glutamyl Transferase and Coronary Atherosclerotic Plaque Vulnerability: An Optical Coherence Tomography Study. Wang J, Li X, Pu J, et al. BioMed Research International. 2019;2019:9602783. doi:10.1155/2019/9602783.
Gamma-Glutamyltransferase and Risk of Cardiovascular Mortality: A Dose-Response Meta-Analysis of Prospective Cohort Studies. Wang J, Zhang D, Huang R, Li X, Huang W. PloS One. 2017;12(2):e0172631. doi:10.1371/journal.pone.0172631.
Association of Gamma-Glutamyltransferase Levels With Total Mortality, Liver-Related and Cardiovascular Outcomes: A Prospective Cohort Study in the UK Biobank. Ho FK, Ferguson LD, Celis-Morales CA, et al. EClinicalMedicine. 2022;48:101435. doi:10.1016/j.eclinm.2022.101435.
Dose-Response Relationship Between Gamma-Glutamyltransferase and the Risk of Atherosclerotic Cardiovascular Diseases in Korean Adults. Jeon J, Kim DH, Kim W, et al. Atherosclerosis. 2020;292:152-159. doi:10.1016/j.atherosclerosis.2019.11.004.
Liver Enzymes and Risk of Cardiovascular Disease in the General Population: A Meta-Analysis of Prospective Cohort Studies. Kunutsor SK, Apekey TA, Khan H. Atherosclerosis. 2014;236(1):7-17. doi:10.1016/j.atherosclerosis.2014.06.006.
The Role of Oxidative Stress in Hyperuricemia and Xanthine Oxidoreductase (XOR) Inhibitors. Liu N, Xu H, Sun Q, et al. Oxidative Medicine and Cellular Longevity. 2021;2021:1470380. doi:10.1155/2021/1470380.
Uric Acid Shown to Contribute to Increased Oxidative Stress Level Independent of Xanthine Oxidoreductase Activity in MedCity21 Health Examination Registry. Kurajoh M, Fukumoto S, Yoshida S, et al. Scientific Reports. 2021;11(1):7378. doi:10.1038/s41598-021-86962-0.
Relationship Between Oxidative Stress and Inflammation in Hyperuricemia: Analysis Based on Asymptomatic Young Patients With Primary Hyperuricemia. Zhou Y, Zhao M, Pu Z, Xu G, Li X. Medicine. 2018;97(49):e13108. doi:10.1097/MD.0000000000013108.
RAGE Deficiency Obstructs High Uric Acid-Induced Oxidative Stress and Inflammatory Response. Zhao H, Lv J, Chen B, et al. International Immunopharmacology. 2025;151:114316. doi:10.1016/j.intimp.2025.114316.
Serum Uric Acid Predicts Changes in Reports of Non-Gouty Chronic Pain: A Prospective Study Among Women With Inflammatory and Non-Inflammatory Pain. Andersson HI, Leden I. Rheumatology International. 2012;32(1):193-8. doi:10.1007/s00296-010-1600-5.
Chronic Musculoskeletal Complaints and Subgroups With Special Reference to Uric Acid. Aarflot T, Bruusgaard D. Scandinavian Journal of Rheumatology. 1994;23(1):25-9. doi:10.3109/03009749409102131.
Hyperuricemic Persons Use More Analgesics Than Normouricemic-Is Asymptomatic Hyperuricemia Really Asymptomatic?. Timsans J, Kauppi JE, Rantalaiho V, et al. BMC Medicine. 2025;:10.1186/s12916-025-04573-2. doi:10.1186/s12916-025-04573-2.
Uric Acid Levels Correlate With Sensory Nerve Function in Healthy Subjects. Abraham A, Katzberg HD, Lovblom LE, Perkins BA, Bril V. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 2019;46(3):337-341. doi:10.1017/cjn.2019.9.
Serum Urate Levels Alter the Spatial Distribution of Urate Crystals in Synovium and Correlate With Synovitis and Pain in Non-Gout Female Patients With Anteromedial Knee Osteoarthritis. Xu H, Wang P, Fu H, et al. Arthritis & Rheumatology (Hoboken, N.J.). 2025;. doi:10.1002/art.43337.
Humoral Innate Immunity and Acute-Phase Proteins. Mantovani A, Garlanda C. The New England Journal of Medicine. 2023;388(5):439-452. doi:10.1056/NEJMra2206346.
Serum or Plasma Ferritin Concentration as an Index of Iron Deficiency and Overload. Garcia-Casal MN, Pasricha SR, Martinez RX, Lopez-Perez L, Peña-Rosas JP. The Cochrane Database of Systematic Reviews. 2021;5:CD011817. doi:10.1002/14651858.CD011817.pub2.
Evaluation of Hyperferritinemia Causes in Rheumatology Practice: A Retrospective, Single-Center Experience. Üsküdar Cansu D, Üsküdar Teke H, Cansu GB, Korkmaz C. Rheumatology International. 2021;41(9):1617-1624. doi:10.1007/s00296-021-04935-y.
Association Between Serum Ferritin Level and Fibromyalgia Syndrome. Ortancil O, Sanli A, Eryuksel R, Basaran A, Ankarali H. European Journal of Clinical Nutrition. 2010;64(3):308-12. doi:10.1038/ejcn.2009.149.
The Risk of Fibromyalgia in Patients With Iron Deficiency Anemia: A Nationwide Population-Based Cohort Study. Yao WC, Chen HJ, Leong KH, et al. Scientific Reports. 2021;11(1):10496. doi:10.1038/s41598-021-89842-9.
Copper and Iron as Unique Trace Elements Linked to Fibromyalgia Risk. Zeng W, Hu M, Ma L, Huang F, Jiang Z. Scientific Reports. 2025;15(1):4019. doi:10.1038/s41598-025-86447-4.
Oxidative Stress in Fibromyalgia: From Pathology to Treatment. Assavarittirong C, Samborski W, Grygiel-Górniak B. Oxidative Medicine and Cellular Longevity. 2022;2022:1582432. doi:10.1155/2022/1582432.
Serum Iron and Iron Stores in Non-Anemic Patients With Fibromyalgia. Mader R, Koton Y, Buskila D, Herer P, Elias M. Clinical Rheumatology. 2012;31(4):595-9. doi:10.1007/s10067-011-1888-x.
Coenzyme Q for Patients With Cardiovascular Disease: JACC Focus Seminar. Raizner AE, Quiñones MA. Journal of the American College of Cardiology. 2021;77(5):609-619. doi:10.1016/j.jacc.2020.12.009.
Can Coenzyme Q10 Improve Clinical and Molecular Parameters in Fibromyalgia?. Cordero MD, Alcocer-Gómez E, de Miguel M, et al. Antioxidants & Redox Signaling. 2013;19(12):1356-61. doi:10.1089/ars.2013.5260.
Coenzyme Q10 for Heart Failure. Al Saadi T, Assaf Y, Farwati M, et al. The Cochrane Database of Systematic Reviews. 2021;(2):CD008684. doi:10.1002/14651858.CD008684.pub3.

Emphasis on Education

Accurate Clinic promotes patient education as the foundation of it’s medical care. In Dr. Ehlenberger’s integrative approach to patient care, including conventional and complementary and alternative medical (CAM) treatments, he may encourage or provide advice about the use of supplements. However, the specifics of choice of supplement, dosing and duration of treatment should be individualized through discussion with Dr. Ehlenberger. The following information and reference articles are presented to provide the reader with some of the latest research to facilitate evidence-based, informed decisions regarding the use of conventional as well as CAM treatments.

For medical-legal reasons, access to these links is limited to patients enrolled in an Accurate Clinic medical program.

Should you wish more information regarding any of the subjects listed – or not listed – here, please contact Dr. Ehlenberger. He has literally thousands of published articles to share on hundreds of topics associated with pain management, weight loss, nutrition, addiction recovery and emergency medicine. It would take years for you to read them, as it did him.

For more information, please contact Accurate Clinic.

Supplements recommended by Dr. Ehlenberger may be purchased commercially online

Please read about our statement regarding the sale of products recommended by Dr. Ehlenberger.